Pharmacovigilance: Partnering for Patient Safety
20 November 2012, Geneva
On 20 November 2012, the IFPMA hosted a Geneva Pharma Forum titled “Pharmacovigilance: Partnering for Patient Safety.” With a special focus on biotherapeutic medicines, the event highlighted the role that pharmacovigilance systems play in assessing the safety profile of a medicine throughout its lifecycle and in protecting patients.
Moderated by Dr. Otmar Kloiber, Secretary General of the World Medical Association, the event featured presentations from Dr. Shanthi Pal (WHO Program Manager for Pharmacovigilance), Dr. Fermin Ruiz de Erenchun (Roche; Chair of IFPMA Biotherapeutics Group) and Mr. Jeremiah Mwangi (Director of External Relations for the International Association of Patient Organizations).
The speakers discussed the work carried out by their respective organizations to highlight the importance of developing and implementing pharmacovigilance standards and of raising public awareness. They also discussed the recent European Union pharmacovigilance legislative developments. Because biotherapeutic medicines are more complex products with distinct product characteristics compared to most chemically-synthesized small molecule medicines, the identification and traceability of individual biotherapeutic medicines are essential, and all stakeholders have a role in ensuring robust pharmacovigilance for biotherapeutic medicines.